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Background: The transcription factor Hes3 regulates the growth of neural and brain cancer stem cells.
Results:Hes3 regulates growth, gene expression, evoked insulin release in cultured insulinoma cells, and sensitivity to strepto-
zotocin in vivo.
Conclusion: Hes3 is a novel regulator of cellular functions of importance in diabetes.
Significance: Introducing Hes3 and its regulators in diabetes research may provide new opportunities for the design of novel
therapeutics.
The transcription factor Hes3 is a component of a signaling
pathway that supports the growth of neural stem cells with pro-
found consequences in neurodegenerative diseasemodels. Here
we explored whether Hes3 also regulates pancreatic islet cells.
We showed thatHes3 is expressed in human and rodent pancre-
atic islets. Inmouse islets it co-localizes with alpha and beta cell
markers. We employed the mouse insulinoma cell line MIN6 to
perform in vitro characterization and functional studies in con-
ditions known to modulate Hes3 based upon our previous work
using neural stemcell cultures. In these conditions, cells showed
elevated Hes3 expression and nuclear localization, grew effi-
ciently, and showed higher evoked insulin release responses,
compared with serum-containing conditions. They also exhib-
ited higher expression of the transcription factor Pdx1 and
insulin. Furthermore, they were responsive to pharmacolog-
ical treatments with the GLP-1 analog Exendin-4, which
increased nuclear Hes3 localization. We employed a transfec-
tion approach to address specific functions of Hes3. Hes3 RNA
interference opposed cell growth and affected gene expression
as revealed by DNA microarrays. Western blotting and PCR
approaches specifically showed that Hes3 RNA interference
opposes the expression of Pdx1 and insulin. Hes3 overexpres-
sion (using a Hes3-GFP fusion construct) confirmed a role of
Hes3 in regulating Pdx1 expression. Hes3 RNA interference
reduced evoked insulin release. Mice lacking Hes3 exhibited
increased islet damage by streptozotocin. These data suggest
roles of Hes3 in pancreatic islet function.
The basic helix-loop-helix transcription factor Hes3 is a
member of the Hes/Hey gene family that regulate developmen-
tal processes in progenitor cells from various tissues (1–7).
Family members such as Hes1 and Hes5 are direct transcrip-
tional targets of the cleaved intracellular domain of the Notch
receptor (8). Hes3 stands out within this family as an indirect
target of a non-canonical branch of the Notch signaling path-
way (9). Specifically, in rodent neural stem cell (NSC)3 cultures,
activation of the Notch receptor by soluble forms of the Delta4
and Jagged1 ligands induces the PI 3-kinase-dependent phos-
phorylation of Akt, mammalian target of rapamycin, STAT3,
on serine residue 727, and subsequent induction of Hes3 tran-
scription leading to increased cell survival and growth (10).
Another activator of the Akt/mammalian target of rapamycin/
STAT3-serine pathway, insulin, also induces Hes3 transcrip-
tion and promotes cell growth (11). Hes3 is a functional medi-
ator of this pathway in normal and cancerous tissues. NSC
cultures from the subventricular zone of adult Hes3 null mice
can be established but they are non-responsive to treatments
that normally promote Hes3 expression and increase their
number such as Delta4 and insulin (11). Inhibition of Hes3
expression by RNA interference in cultures of primary human
brain cancer stem cells opposes their growth (12).
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Hes3 has two forms: Hes3a and Hes3b (13). Hes3a cannot
bind DNA but can still form heterodimers with other basic
helix-loop-helix factors. Hes3b can both bind DNA and form
heterodimers. The expression of another member of the Hes/
Hey gene family, Hes1, and of other basic helix-loop-helix fac-
tors exhibit an oscillatory pattern (2). Oscillatory expression of
the basic helix-loop-helix Ascl1 characterizes the self-renewing
state, whereas sustained expression of specific genes results in
fate determination, suggesting oscillatory versus sustained
expression patterns are means of regulating cell fate.
Several studies support a role of Hes3 and its regulators in a
number of normal and cancerous tissues, and in various regen-
erative processes. Macrophage inhibitory factor induces Hes3
expression and promotes NSC/progenitor cell proliferation
and maintenance (14). Delta4, alone or in combination with
other treatments such as basic fibroblast growth factor and epi-
dermal growth factor (EGF), increases the number of endoge-
nous progenitors in several areas of the adult brain (10, 11,
15–17). Delta4 induces Hes3 expression and promotes the acqui-
sition of the definitive NSC fate from iPS-derived primitive NSCs
(18). When Hes3 is “knocked out” from the Hes1:Hes5 double-
mutantmouse line, neuroepithelial cells prematurely differentiate
into neurons during embryonic development (19). A phosphomi-
metic STAT3-serine construct promotes prostate tumorigene-
sis independently of the JAK-STAT pathway (20), which
involves the phosphorylation of STAT3 on tyrosine 705 (21).
Notch-dependent STAT3-serine phosphorylation contributes
to the growth of embryonic stem cell-derived NSCs following
induction of Hoxb1 expression (22). The anti-tumor efficacy of
a smallmolecule inhibitor of-secretase, an enzyme involved in
Notch receptor activation (3), can be predicted by the level of
expression of Hes3 in breast cancer xenograft models (23).
Here, using a mouse insulinoma cell line (MIN6) and obser-
vations in isolated and dissociated/cultured mouse and human
islets, we addressed possible functions ofHes3, whichmay be of
interest to the field of diabetes. We showed that Hes3 is
expressed in mouse and human pancreatic islets and that
geneticmanipulation ofHes3 inMIN6 cells affects gene expres-
sion; key genes regulated include insulin and pancreatic and
duodenal homeobox 1 (Pdx1), a transcription factor involved in
pancreatic development and diabetes (24). In addition, Hes3
regulates the cell number and evoked insulin release. Using a
Hes3nullmouse strainwhere theHes3 genewas replaced by the
reporter lacZ gene (25), we confirmed Hes3 expression in the
adult pancreatic islet and induction following streptozotocin
(STZ)-induced damage, and showed that in the absence of
Hes3, STZ-induced damage is more pronounced, as indicated
by reduced beta cell number and increased blood glucose levels
in vivo. Taken together, these findings suggest that Hes3 may
have important roles in pancreatic islet function.
EXPERIMENTAL PROCEDURES
Cell Culture—MIN6 cells were grown in either serum con-
tainingmedium (DMEM(Invitrogen, 61965-026), 15% fetal calf
serum (Biochrom Superior, F0615), 70 M 2-mercaptoethanol
(Sigma, M6250), 100 g/ml of Pen-Strep (Invitrogen, 15140-
122)), or serum-free N2medium (DMEM-F12 (Sigma, D8062),
100 g/ml of apo-transferrin (Sigma, T2036), 20 nM progester-
one (Sigma, P8783), 100 M putrescine (Sigma, P5780), 30 nM
selenite (Sigma, S5261), and 100 g/ml of Pen-Strep)). To
examine changes in the properties of MIN6 cells under differ-
ent culture conditions, cells were first maintained in serum
containing medium for 5 days. Cells were then passaged and
grown under serum-free conditions for another 5 days. The
cells were then passaged again, back into serum containing
medium (“RC” for return condition) for an additional 5 days
prior to analysis. Serum and no serum controls were run in
parallel in which the cells weremaintained in either serum con-
taining or serum-free conditions for the final 10 days of the
experiment. For Exendin-4 treatments, cells were seeded at
50,000 cells/24-well plate well and treated with different con-
centrations of Exendin-4 (Biotrend, BP0111) beginning at 24 h
after plating for different times, as indicated. For the sustained
treatments, Exendin-4 was added every 2 days during medium
changes, and cells were fixed and immunostained at day 5. In
this paper, we denote serum-containingmediumas “CC” (com-
mon conditions) and serum-free medium as “DC” (defined
conditions).
JAK inhibitor treatments were performed on MIN6 cells
seeded at 50,000 cells/well in a 24-well plate in DC. The inhib-
itor (Calbiochem 420097) was added to the culture medium
daily fromday 1 to 5; cell fixation and visualizationwas onday 5.
DNA Microarray—RNA was extracted from MIN6 cells
grown in T75 flasks under the above mentioned culture condi-
tions. For experiments using Hes3 siRNA, cells were trans-
fected at 24 h after seeding. RNA integrity number for each
sample was checked using Agilent Bioanalyzer (Agilent Michi-
gan).Quadruplicate samples froma single experimentwere run
in DNA microarray equipment (Affymetrix). Volcano plots,
heat maps, and statistics were generated using the R-2.15.2
software.
RNA Isolation and Reverse Transcriptase PCR—RNA was
extracted from whole pancreas or MIN6 cells using the High
Pure RNA isolation kit (Roche Applied Science, 11828665001)
and reverse transcribed using Promega M-MLV reverse tran-
scriptase (Promega, M170B). PCR was performed for total
Hes3,Hes3a,Hes3b, Pdx1, insulin, andGAPDH (for primer list,
please see below) using Dream Taq Green DNA polymerase
(Thermo Scientific, EP0711).
Western Blotting—MIN6 cells were grown in 6-well plates for
5 days, then lysed with 500 l of CytoBuster Protein Extraction
Reagent (Novagen, 71009-3) containing protease inhibitors
(Sigma, P8340). Samples were resolved by Western blotting
using standard techniques.
Immunohistochemistry/Immunocytochemistry—Mouse pan-
creata were fixed by transcardial perfusion with 4% PFA fol-
lowed by post-fixation overnight at 4 °C. Human isolated islets
were fixed with 4% PFA for 30 min. The tissue was cryopro-
tected with 30% sucrose and embedded in OCT compound
(Sakura, 4583). 12–14-m sections were cut and mounted on
glass slides. MIN6 cells were fixed in 4% PFA for 30 min. Both
the sections and cells were permeabilized in 0.1% Triton X-100
in PBS andblocked in 5%powderedmilk and 0.1%TritonX-100
in PBS prior to incubation with primary antibody. Images were
taken using a laser confocal microscope (LEICA, Germany).
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Detection of -Galactosidase Enzymatic Activity—Tissue sec-
tions were washed 3  5 min in LacZ wash buffer (PBS, 0.01%
sodiumdeoxycholate, SigmaD6750, 0.002%Nonidet P-40, Roche
11754599001, and 2 mM MgCl2, Sigma 630063) and incubated
overnight in LacZ staining buffer (LacZ buffer, 5 mM potassium
ferrocyanide, Sigma, 736716; 5mMpotassium ferricyanide, Sigma,
702587) containing 2.45mM5-bromo-4-chloro-3-indoxy--D-ga-
lactopyranoside (X-Gal, ROTH, R0404). Sections were then visu-
alized using brightfield microscopy.
Cell Proliferation—MIN6 cell proliferationwas determined 4
days after the final cell passage by incubating the cells with
10 M EdU for 8 h followed by visualization using the Click-IT
EdU Alexa Fluor 594 Imaging Kit (Invitrogen, C10339).
Cell Viability Assay—Adherent MIN6 cells were cultured on
sterile glass coverslips in CC, DC, and RC for 5 days. Cells were
washed briefly with PBS and incubated with 4 M Eth-D solu-
tion (LIVE/DEAD Viability/Cytotoxicity Kit for mammalian
cells, Invitrogen, L-3224) for 30 min. Cells were fixed with 4%
PFA and imaged.
Insulin Secretion Assay (with Variable KCl)—Combined glu-
cose/KCl stimulated insulin production assay was performed
onMIN6 cells as described in Ref. 26 using a Rat Insulin ELISA
kit (Mercodia, 10-1250-01) and detected with a microplate
reader (TECAN). Glucose concentrations were as follows: rest-
ing, 0 mM; stimulated, 25 mM. KCl concentrations were as fol-
lows: resting, 5 mM; stimulated, 55 mM.
Insulin Secretion Assay (with Non-variable KCl)—For these
experiments, cells were maintained in a low KCl concentration
(5 mM), which was not altered between resting and stimulated
states. Glucose concentrations were as follows: resting, 2.8 mM;
stimulated, 20 mM.
Hes3 Knockdown and Overexpression—MIN6 cells were
plated at 50,000 cells/well in a 24-well plate. 24 h later, cells
were transfected with Hes3 siRNA (2M final concentration in
the culture medium) or scrambled control siRNA (Santa Cruz,
sc-37942 and sc-37007) using DharmaFECT4 (Thermo Scien-
tific, T-2004-001) as described by the manufacturer. Cells were
assayed 12–24 h after transfection for changes in proliferation
and in gene expression as determined by gene array analysis,
immunocytochemistry, and Western blot. For Hes3 overex-
pression, MIN6 cells were transfected using Lipofectamine
2000 as described by the manufacturer with either pcDNA3.1
containing a C terminus GFP-tagged Hes3a gene or with an
empty vector. Cells were cultured up to day 5, immunostained,
and imaged using laser confocal microscopy.
Mouse Models of Diabetes—For high dose streptozotocin
(Sigma, S0130) experiments, 8-week-old C57Bl/6J mice were
injected intraperitoneally with a single dose of 150 mg/kg of
streptozotocin or with PBS (vehicle control). For low dose
streptozotocin experiments, 8-week-old C57Bl/6J mice were
injected intraperitoneally with 5 daily doses of 50 mg/kg of
streptozotocin or with PBS (vehicle control). Pancreata were
extracted 4 weeks later.
Db/Db and Ob/Ob Mice—Pancreata were harvested from
10-month-old mice homozygous for the diabetes spontaneous
mutations, Lepr db or Lep ob. C57Bl/6J mice served as control.
C57BLKS/J mice were used as controls.
Total Body Irradiation of Mice—8-Week-old C57Bl/6J mice
were administered a single 4-gray dose of irradiation for 3 min
and 41 s. Pancreata were extracted 5 days after irradiation.
In Vivo Blood Glucose Measurements—One droplet of blood
from a tail clip incision was placed on a glucose test strip and
read using a glucometer (ACCU-CHEK Aviva, Roche Applied
Science).
In Vivo Intraperitoneal Glucose Tolerance Test—Mice were
fasted for 16 h (overnight) prior to the experiment. Glucose
levels were measured 0, 15, 30, 60, 90, and 120 min after intra-
peritoneal injection of a 20% glucose solution (2 g of glucose/kg
of body weight) (27).
Mouse Pancreatic Islet Isolation—Mice were euthanized and
injected with Working Enzyme solution (Dissociation buffer,
Collagenase, Sigma, C7657) through the bile duct to perfuse the
pancreas. Pancreas tissue was incubated for 20 min at 37 °C on
a rocking platform at 100 rpm for dissociation. Dissociated tis-
sue was washed with Quenching buffer (Hank’s balanced salt
solution, Invitrogen, 14025092; 10% FBS, Biochrom) and fil-
tered. Different gradients of Ficoll (Sigma, F637) were applied
to collect the islets. Islets were resuspended in Islet Culture
Medium (CMRL 1066, Invitrogen, PL000676; 10% FBS Bio-
chrom; PenStrep, Invitrogen). In this medium, hand-picking of
islets was performed. Following this, islets were placed in the
appropriate culture medium for experimentation as described
under “Results.”
Human Pancreatic Islets—Human isolated islets (4 prepara-
tions) were obtained by the Diabetes Research Group, King’s
College London, UK.
Dissociation/Culture of Human Pancreatic Islets—Human
pancreatic islets were washed 3 times with PBS at room tem-
perature and dissociated using 0.05% trypsin/EDTA (Invitro-
gen, 25300) for 2 min at 37 °C. Cells were then seeded at a
density of 50,000 cells per well in a 24-well plate and cultured
either in Islet Culture Medium (as described in mouse pancre-
atic islet isolation) or N2medium for 48–72 h. Cells were fixed
with 4% PFA, immunostained, and imaged.
Statistical Analysis—Results shown are the mean  S.D. or
S.E., as noted in the figure legends. Experiments were per-
formed in triplicate, unless otherwise noted. Asterisks identify
experimental groups that were significantly different (p value
0.05) from control groups by the Student’s t test (paired, two-
sided) (Microsoft Excel).
Antibodies Used—Primary antibodies used were: anti-HES3
1:100 (Santa Cruz, M-135, sc-25393), anti-Pdx1 1:1000
(Abcam, ab47383), anti-insulin 1:200 (GeneTex, GT X27842),
anti-glucagon 1:200 (GeneTex, K79bB10), anti-somatostatin
1:200 (GeneTex, YC7), and anti-NKX6.1 1:200 (R&D Systems,
AF5857). Secondary antibodies used were: donkey anti-rabbit
IgG (HL) 594 (Dianova, 711-505-152), donkey anti-goat IgG
(HL) 488 (Dianova, 705-486-147), donkey anti-guinea pig IgG
(HL) 488 (Dianova, 706-486-148), donkey anti-guinea pig
IgG (HL) 649 (Dianova, 706-496-148), donkey anti-mouse
IgG (HL) 649 (Dianova, 715-496-150), and donkey anti-
rat IgG (HL) 649 (Dianova, 712-496-150). All secondary anti-
bodies were diluted 1:500 in blocking buffer and incubated at
room temperature for 1–2 h. DAPI is applied at 1:10,000 dilu-
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tion for 15 min for nuclear staining. Images were taken using a
laser confocal microscope (LEICA, Germany).
PCR Primers—The primers used were: MuHes3a-F, AAGC-
TCCCTGCCATAGCGGA;MuHes3a-R,ATGCGTGCACGGC-
GCTTCTT;MuHes3b-F, ACATCACAGCATGGGCACCGAG-
CCCACATC; MuHes3b-R, GTTGATGCGTGCACGGCGC-
TTCTTC; MuHes3-F, ATCTCCAAGCCTCTGATGGAGAA;
MuHes3-R, AGCTTTCGTTTCCGTATCTGATG; HuHes3-F,
GAGAAGCCTTCAGAACTCCTTGC;HuHes3-R,CTGCCGA-
CCTCATCTCCGCG; MuPdx1-F, CCACCCCAGTTTACAAG-
CTC; MuPdx1-R, TGTAGGCAGTACGGGTCCTC; HuPdx1-F,
CTTTCTCCTCCTCCTCCTTCTA; HuPdx1-R, GGTCATAC-
TGGCTCGTGAATAG; MuInsulin-F, GACCAGCTATAATC-
AGAGACC; MuInsulin-R, AGTTGCAGTAGTTCTCCAGCTG;
MuHes1-F, TCTCTCCTTGGTCCTGGAATA; Mu-Hes1-R, CT-
TCGCCTCTTCTCCATGATAG; MuGAPDH-F, CTGGAG-
AAACCTGCCAAGTA; MuGAPDH-R, TGTTGCTGTAGC-
CGTATTCA; HuGAPDH-F, GATTCCACCCATGGCAAA-
TTC; and HuGAPDH-R, GTCATGAGTCCTTCCACGA-
TAC.
RESULTS
Hes3 Is Expressed in Adult Pancreatic Islets—Hes3 immuno-
labeling of isolated adult human pancreatic islets showed
expression of Hes3 (counterstained for glucagon, insulin, Pdx1,
somatostatin, and Nkx6.1) (Fig. 1A). Western blot and PCR
analysis confirmed Hes3 expression in protein and RNA
extracts from isolated human (hu) and mouse (mu) pancreatic
islets (Fig. 1, B and C). Isolated adult human pancreatic islets
can be placed in culture for research or transplantation pur-
poses (28). Typically, these cells are cultured in serum-contain-
ing media. However, in NSC cultures, serum inclusion in the
culture medium opposes the nuclear localization of Hes3, and
this may suppress transcriptional functions (9). For this pur-
pose, we cultured dissociated human islet cells in both com-
monly used serum-containing (“CC”) and serum-free, defined
(“DC”) conditions. We point out that these two media compo-
sitions differ in various aspects, as detailed under “Experimen-
tal Procedures,” not only in terms of the presence or absence of
serum. Under both conditions, cells grew efficiently and the
cultures maintained expression of Pdx1, Nkx6.1, and insulin
(Fig. 1, D and E). The incidence of cells with nuclear Hes3, the
intensity of Hes3 label, the incidence of cells expressing insulin,
and the incidence of cells co-expressing Hes3 and insulin was
higher in DC than in CC (Fig. 1, F–I).
Hes3 immunolabeling of the adult mouse pancreas showed
that Hes3 is expressed in a significant proportion of beta and
alpha cells (Fig. 1, J-K). (Insets are images of the cell nuclei
stained with DAPI.) Hes3 immunofluorescence appeared post-
natally at approximately day 8 and gradually increased until
approximately day 20 (Fig. 1L). (Insets show merged channel
images.) PCR analysis of total adult mouse pancreas confirmed
the expression of both Hes3 isoforms (Hes3a and Hes3b) (Fig.
1M).
Hes3 Is Expressed in Cultured MIN6 Cells under Defined
Growth Conditions—To address functional roles of molecular
mechanisms in pancreatic islet cells, the mouse insulinoma cell
line MIN6 is a common tool that allows the assessment of cell
growth and glucose-stimulated insulin secretion (29). MIN6
cells are typically cultured in CC.We also cultured them in DC
to assess whether, like with the human cells, these conditions
promote nuclear Hes3 expression. In some experiments, fol-
lowing growth in DC, we passaged cells back in serum-contain-
ing conditions (“RC”) to assess the reversibility of the cell state.
Cells grew efficiently in all three conditions (Fig. 2A). (Per-
cent of cells that incorporate EdU following an 8-h EdU pulse:
CC: 47.7 8.4%; DC: 15.0 2.1%; RC: 49.8 9.7%.) In CC and
RC, no cells exhibited nuclear localization of Hes3. In contrast,
in DC,15% of cells exhibited strong nuclear Hes3 localization
at each point in time (Fig. 2B). In DC, cells also exhibited a
higher incidence of Pdx1 expression. Cells in all three condi-
tions exhibited low cell death rates, as assessed by ethidium
bromide incorporation. (Percent of cells that incorporate
ethidium bromide during a 30-min pulse before cell fixation:
CC: 6.2 0.3%; DC: 4.4 0.4%; RC: 5.5 0.2%.) Gene expres-
sion differed between CC and DC, and between DC and RC, as
revealed by DNA microarray analysis (Fig. 2C). In DC, protein
expression of Pdx1 and insulin were higher than in CC or RC
(Fig. 2D).
When challenged with a combination of glucose and KCl
following a period of glucose starvation (26), cells in all three
conditions responded by releasing insulin (Fig. 2, E and F). In
DC, the stimulation index was elevated compared with CC and
RC.
MIN6 Cells Cultured in DC Respond to Pharmacological
Stimulation by Exendin-4—The GLP-1 analog Exendin-4
activates signal transduction pathways that stimulate insulin
release (30). Exendin-4 operates via Akt/Irs2 and mammalian
target of rapamycin (31–34), signaling components that in
NSCs lead to Hes3 induction (10).
Treatment with 0, 20, and 50 nM Exendin-4 for 4 h, 6 h, 12 h,
24 h, or 5 days did not show ameasurable effect onHes3 expres-
sion/subcellular localization as assessed by immunocytochem-
istry (data not shown). However, treatment with 200 nM Exen-
din-4 over the same time course up to 24 h showed an increase
in Hes3 expression (Fig. 3, A–C). In contrast, none of these
treatments resulted in nuclear Pdx1 localization (Fig. 3, A and
B, and data not shown).
Treatment with 200 nM Exendin-4 for 5 days significantly
increased nuclearHes3 localization (Fig. 3,D and E). This treat-
ment, as well as 50 and 100 nM Exendin-4 for 5 days, also sig-
nificantly increased nuclear Pdx1 expression.
In CC fewer than 3% of the cells exhibit nuclearHes3 or Pdx1
expression. A 200 nM Exendin-4 treatment for 5 days induced a
significant increase in the percentage of cells expressing nuclear
Hes3 and nuclear Pdx1; nuclear Hes3 and Pdx1 colocalized in
the same cells (Fig. 3, F and G).
Hes3 Regulates MIN6 Cell Number and Gene Expression—
Hes3 RNA interference reduced cell number inDC; in contrast,
it had no significant effect in CC (Fig. 4, A and B, and data not
shown). Hes3 RNA interference in DC induced significant
changes in gene expression as revealed by an Affymetrix DNA
microarray experiment; Hes3 knockdown in CC had a smaller
effect on gene expression (Fig. 4, C and D; Table 1).
Hes3 RNA interference reduced the expression of Pdx1 and
insulin in DC as assessed by Western blotting and PCR
Hes3 Regulates Pancreatic Islet Cell Functions
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FIGURE 1. Hes3 is expressed in adult pancreatic islets and dissociated cultures of pancreatic islet cells. A, confocal immunohistochemical images
of sections from isolated human pancreatic islets show nuclear Hes3 expression in cells co-expressing glucagon, insulin, Pdx1, somatostatin, and Nkx6.1
(image widths: 246 m). B, Western blot analysis shows expression of Hes3, along with Pdx1, in isolated human and mouse pancreatic islets. C, PCR
analysis from isolated human pancreatic islets shows Hes3, Pdx1, and insulin expression. D, cultures from dissociated human pancreatic islets in CC and
DC exhibit Pdx1 and Nkx6.1 expression (image widths: 387 m). E, cultures from dissociated human pancreatic islets in CC and DC exhibit insulin and
Hes3 expression (image widths: 157 m). F–I, quantification of the percentage of cells with nuclear Hes3 staining, Hes3 immunolabel intensity,
percentage of cells expressing insulin, and percentage of cells expressing both Hes3 and insulin, in cultures from dissociated human pancreatic islets in
CC and DC (signal intensity was measured using the Fiji image processing software. Data are mean from 500 cells; error bars represent S.D. A total of
4 human islet preparations were used to generate these data.) J, confocal immunohistochemical images of sections from the adult mouse pancreas
show that Hes3 is expressed in the nucleus of pancreatic islet cells co-expressing glucagon, insulin, Pdx1, somatostatin, and Nkx6.1 (image widths: 246
m; insets show cell nuclei stained with DAPI). K, quantification of the percentage of cells in the islet that express Hes3, the percentage of Pdx1 positive
cells in the islet that express Hes3, the percentage of Pdx1 positive cells that co-express insulin and Hes3, and the percentage of glucagon positive cells
that express Hes3 in 4-, 8-, and 15-week-old mice (n  3; errors bars represent S.E.). L, immunohistochemical images of sections from the postnatal
mouse pancreas show that Hes3 immunoreactivity appears postnatally (P8, postnatal day 8, etc.). The main images show Hes3 in white and insets are
co-stainings of Hes3 with insulin and glucagon (image widths: 246 m). M, Hes3 mRNA expression in cDNA from total pancreas from mice of different
ages (postnatal days 3 to 21) (data are shown for both isoforms of Hes3: Hes3a and Hes3b).
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approaches (Fig. 4, E and F). Transient overexpression with a
vector with the GFP gene fused to Hes3 revealed that all (100%)
of the transfected cells exhibited Pdx1 expression. In contrast,
cells transfected with the control GFP vector did not have a
greater incidence of Pdx1 expression thannon-transfected con-
trols (15%) (Fig. 4G).
Hes3 Regulates Evoked Insulin Release in MIN6 Cells—Hes3
RNA interference reduced insulin content, the amount of
FIGURE 2. Hes3 is expressed in cultured MIN6 cells under defined conditions. A, cells propagate under all three culture conditions as shown by EdU
incorporation (representative immunocytochemistry images shown; insets represent DAPI staining) (image width: 387 m). B, DC promote nuclear Hes3
localization and increase nuclear Pdx1 localization. Nuclear Hes3 and Pdx1 co-localize. (representative immunocytochemistry images shown) (image widths:
450 m). C, culture conditions affect gene expression profiles as revealed by Affymetrix DNA microarrays. D, culture conditions affect Pdx1 expression, and
insulin content (Westernblotting images shown);DC increasePdx1expressionand insulin content; the effects are reversedby re-plating the cells in RC (GAPDH
isusedas thehousekeepinggene). E, released insulinmeasurementsbyELISAunder the threedifferent conditions showthat the cells are responsive toglucose
challenge in all conditions (n 3; errors bars represent S.E. R, resting state; S, stimulated state). F, stimulation indexmeasurements (expressed as%of the value
in CC) by ELISA under the three different conditions show that the cells are responsive to glucose challenge in all conditions (n 3; errors bars represent S.E.).
FIGURE 3.MIN6 cells respond topharmacological stimulation.A, treatmentwith Exendin-4 (200 nM) induces the time-dependent expression of Hes3. Some
of the Hes3 cells co-express Pdx1 (imagewidths: 387m). B, details from A showHes3/Pdx1 co-expression. C, quantification of the effects of Exendin-4 (200
nM in DC) on the percentage of cells with nuclear Hes3 expression, at different time points after treatment (n 3; errors bars represent S.D.).D, Exendin-4 (200
nM for 5 days in DC) increases the nuclear localization of Pdx1 and Hes3; Pdx1 and Hes3 co-localize (representative immunocytochemistry images are shown)
(image widths: 450 m). E, quantification of the effects of Exendin-4 (200 nM for 5 days in DC) on the percentage of cells with nuclear Pdx1 and nuclear Hes3,
compared with controls (n 3; errors bars represent S.E.). F, Exendin-4 (200 nM for 5 days in CC) increases the nuclear localization of Pdx1 and Hes3; Pdx1 and
Hes3 co-localize (representative immunocytochemistry images shown) (imagewidths: 450m).G,quantification of the effects of Exendin-4 (200 nM for 5 days
in CC) on the percentage of cells with nuclear Pdx1 and nuclear Hes3, compared with controls (n 3; errors bars represent S.E.).
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released insulin, and stimulation index as assessed by ELISA
measurements of insulin (Fig. 5, A–C), using a stimulation par-
adigm that includes both glucose and KCl. Using a different
stimulation paradigm that utilizes the same concentration of
low KCl and different glucose concentrations in DC, in both
the resting and stimulated states, we did not observe any
significant stimulated insulin release (insulin content: scram-
bled control siRNA/resting, 28.684 ng  1.553; control
siRNA/stimulated: 25.974 ng  1.805; Hes3 siRNA/resting,
22.541 ng 2.059; Hes3 siRNA/stimulated, 18.193 ng 1.893;
stimulation index: control siRNA: 0.824  0.24; Hes3 siRNA:
1.082 0.62).
Hes3 Null Mice Exhibit Grossly Normal Pancreatic Islet
Marker Expression and Blood Glucose Values—Hes3 null mice
have no obvious phenotype under normal conditions (25).
Indeed, islet morphology and biomarker expression did notFIGURE 4. Hes3 regulates cell number and gene expression in MIN6 cell
cultures. A, Hes3 interference by siRNA in DC opposes their growth (repre-
sentative brightfield images shown) (imagewidth: 450m). B, quantification
of cell number followingHes3 interference inDC. Data are presented as num-
ber of cells per field of view (n 3; errors bars represent S.D.). C and D, Hes3
interference by siRNA in cells cultured in CC and DC induces gene expression
profile changes (2 days after interference). Data are presented as a “volcano”
plot generated fromAffymetrix DNAmicroarrays. The y axis represents statis-
tical confidence (from quadruplicate samples) and the x axis represents fold-
change (logarithmic scale). Red dots represent genes whose expression is
reduced by Hes3 siRNA and green dots those whose expression increases.
Gray dots represent geneswhose expression changes less than 2-fold. E, Hes3
interference opposes Hes3, Pdx1, and insulin protein expression. (Western
blottingdata are shown;GAPDHwasusedas thehousekeepinggene.) F,Hes3
interference opposes Hes3a Hes3b, total Hes3, Pdx1, and insulin gene tran-
scription (PCR data shown; GAPDH was used as the housekeeping gene). G,
Hes3 overexpression induces nuclear Pdx1 localization in DC. In DC, at each
time point,15% of cells exhibit nuclear Hes3 localization. Transient overex-
pression of a control GFP plasmid has no effect on nuclear Pdx1 localization.
The top two rows show examples of GFP-labeled cells with nuclear and non-
nuclear Pdx1. In contrast, overexpressionof aHes3-GFP fusionplasmid results
in 100% of labeled cells exhibiting nuclear Pdx1 (representative immunocy-
tochemistry images shown) (image width: 246 m).
TABLE 1
Gene expression regulation by Hes3 knockdown in MIN6 cells
MIN6 cells were passaged into separate plates and cultured in CC or DC for 1 day
prior to transfection. Cells were transfected with scrambled control siRNA orHes3
siRNA, and total RNA was collected after 4 days in vitro. Gene expression profiles
were determined using an Affymetrix DNA microarray (data are from a single
experimentwith quadruplicate samples; top 10 log2FC values are presented for each
category).
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reveal any obvious differences from wild-type mice (Fig. 6A). PCR analysis for Pdx1 and insulin also revealed levels similar to
wild-type controls (Fig. 6B). Another member of the Hes/Hey
gene family,Hes1, exhibited amarked increase in RNA levels in
islets from the Hes3 null mice.
Fasting blood glucose levels and glucose tolerance test scores
were also normal (Fig. 6C). Likewise, total body weight was also
similar between wild-type and Hes3 null mice (wild-type,
22.6 g 0.3; Hes3/, 20.8 0.3).
Hes3NullMice Exhibit Increased STZ Sensitivity—Following
STZ damage (using either high or low dose STZ protocols),
activation of theHes3a promoterwas significantly enhanced, as
assessed by X-Gal staining (Fig. 7, A and B). When wild-type
mice are subjected to the low STZ damage protocol, blood glu-
cose levels increase 4–5 days after the last STZ injection,
relative to vehicle-treated animals (Fig. 7,C andD). In contrast,
blood glucose levels in Hes3 null mice increased within 2 days
from the last injection. Hes3 null mice reached diabetic blood
glucose levels (	200 mg/dcl) earlier than wild-type controls
(Fig. 7E). Immunohistochemical analysis of the pancreata of
wild-type andHes3 null mice 5 days after the last STZ injection
revealed a decrease in the percentage of insulin and Nkx6.1
cells and an increase in the relative number of glucagon cells
in the pancreatic islets (Fig. 7, F–H).
DISCUSSION
Pancreatic islets demonstrate remarkable plasticity, being
able to alter mass depending on systemic insulin demand (35).
Understanding this mechanism will help us design new thera-
peutic strategies for diabetes.We previously elucidated a signal
transduction pathway that plays important roles regulating the
plasticity of a different cell type, the NSC (9). A key component
is the transcription factor Hes3 (10). Several inputs into Hes3
increase its expression and nuclear localization, and promote
the growth of NSCs in vitro and in vivo (36, 37). In vivo, they
increase the number of Hes3 cells and confer powerful neu-
roprotection in animal models of ischemic stroke and Parkin-
son disease, likely, in part through the release of trophic factors
from Hes3 cells (10, 11, 15, 17, 38).
The choice of culture conditions is key to the appropriate
modeling of a signaling pathway in vitro. Defined culture con-
ditions that omit unknown factors improve reproducibility and
are demonstrably able to model aspects of the biology of NSCs
in vivo (39). Although cells in tissues are exposed to several
serum components within their microenvironment, these pre-
cise conditions that include active cytokines,membrane-bound
FIGURE 5. Hes3 regulates responses to challenge by glucose/KCl in MIN6 cell cultures. A–C, insulin content, released insulin, and stimulation index
measurements by ELISA (stimulation index is expressed as % of control siRNA) following transfection with either a control siRNA or Hes3 siRNA show that
opposingHes3 expression reduces the responsiveness to stimulation inMIN6 cells cultured inDC (n 3; errors bars represent S.E. R, resting state; S, stimulated
state).
FIGURE 6. Hes3 null mice exhibit grossly normal pancreatic islet marker
expression and blood glucose values. A, immunohistochemical detection
of pancreatic isletmarkers in sections fromwholepancreas (imagewidth: 387
m). B, PCR analysis of Pdx1, insulin, Hes3, and Hes1 expression in isolated
islets from wild-type, Hes3 heterozygous, and Hes3 null; pancreatic tissues
after islet removal was also used. C, glucose tolerance test scores are shown
for wild-type and Hes3 null mice (blood glucose was measured at different
time points within a 120-min period. Data representmean S.E. from 7wild-
type and 5 Hes3 null mice).
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receptors, and extracellular matrix components are very diffi-
cult to model in vitro by simply including serum. Regardless of
the culture method, conditions in vitro are non-physiological.
Here, conditions were chosen based on our understanding of
how to maintain the operation of the Hes3 signaling pathway,
allowing us to model this aspect of pancreatic islet cells. Key
FIGURE 7. Hes3 null mice exhibit a more pronounced effect following STZ-induced damage. A, X-Gal staining of pancreatic islets from Hes3 null mice
following damage by the high STZ protocol at different time points after STZ injection (image width: 223m). B, X-Gal staining of pancreatic islets from Hes3
null mice following damage by the low STZ protocol. Images were taken 10 days after vehicle or STZ injection regimen completion (image width: 446m). C,
blood glucose levels inwild-type andHes3 nullmice after control (vehicle) injections. Injectionswere given on five consecutive days starting at day 0.D, blood
glucose levels in wild-type and Hes3 null mice after low dose STZ injections. Injections were given on five consecutive days starting at day 0 (data aremean
S.E. from 8 to 11mice per group). E, quantification of the percentage ofmice that have blood glucose levels over 200mg/dl (i.e. diabetic mice) over the course
of 10 days (data represent the experiment described inD). F, immunohistochemical detection of insulin and glucagon in wild-type and Hes3 null mice treated
with low STZ (images were taken at day 10). Insets show merged channels together with DAPI staining (image width: 267 m). G, immunohistochemical
detection of Nkx6.1 in wild-type and Hes3 null mice treated with low STZ (images were taken at day 10). Insets show merged channels together with DAPI
staining (imagewidth: 267m).H, quantification of the percentage of insulin, glucagon, and Nkx6.1 cells per islet as shown in F andG. Data aremean
S.D. from 30 islets per group.
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features of these conditions are the absence of serum, the pre-
coating of culture plates with polyornithine and fibronectin,
and the use of low oxygen (5%) incubators (40). The ability of
MIN6 cells as well as human primary dissociated islet cells to
efficiently grow in serum-free conditionsmay also be of interest
to drug discovery efforts where the inclusion of serum together
with its many unknown components may render data interpre-
tation difficult. By applying our understanding of NSC signal
transduction to pancreatic islet cell systems, we demonstrate
thatHes3 is expressed in themouse and humanpancreatic islet,
and that it regulates several functions in vitro, including cell
growth and evoked insulin release (Fig. 8A).
There may be a large number of genes downstream of
Hes3 that affect pancreatic islet function. A DNA microarray
approach revealed that Hes3 in CC positively regulates Cckbr
(cholecystokinin B receptor), a gene involved in pancreatic islet
neogenesis (41–44) (Table 1). It may be of interest to address a
potential role of Hes3 in neogenesis, possibly intercepting with
gastrin signaling through its receptor (Cckbr), in future studies.
The DNA microarray data also show that, among the top
genes regulated by Hes3 knockdown, small nucleolar RNAs
appear preferentially and negatively regulated byHes3 in CC. It
is difficult tomake absolute statements on the subcellular local-
ization of Hes3 using a polyclonal antibody; however, it is pos-
sible that because in the two culture conditions Hes3 localiza-
tion appears very different (CC, cytoplasmic; DC, nuclear), data
from these two culture conditions may preferentially represent
passive repressor versus transcriptional functions of Hes3. It is
also possible that the apparent subcellular localization differ-
ences in Hes3 represent different forms of the gene (Hes3a ver-
sus Hes3b) and future studies may address the distinct func-
tions of these two forms. This could be especially important
because, as we show, both forms are present in total pancreas
tissue and the levels of the transcripts appear to be differentially
regulated during postnatal development. In light of recentwork
showing that oscillatory versus sustained expression of Hes/
Hey and other related genes contributes to cell fate specifica-
tion (7), it will be useful to address, in future studies, the regu-
lation of the expression of each Hes3 form.
The repressor activity of Hes3 renders it a difficult gene to
study, being a candidate for transcriptional squelching. Indeed,
stable transfection of MIN6 cells with full-length Hes3b-GFP
results in GFP cells that appear healthy for weeks but form
colonies of only 1, 2, or 3 cells (data not shown). In this paper,
we rely mostly on Hes3 RNA interference, and inferences from
Hes3 overexpression (positive regulation of Pdx1) are corrobo-
rated by Hes3 siRNA experiments.
To identify additional putative mediators of Hes3 manipula-
tion, a more focused approach based on work performed in
other cell types, includingNSCs, was also applied. TheHes/Hey
gene family comprisesmemberswithwidely different functions
in NSCs. For example, whereas Hes3 expression is consistent
with self-renewal, Hes1, through cytoplasmic interactions with
JAK and STAT3, promotes STAT3-tyrosine phosphorylation
and subsequent differentiation to the glial fate (45). Hes1 and
Hes3 also represent two distinct branches of the Notch signal-
ing pathway (Hes1, canonical; Hes3, STAT3-Ser/Hes3 signal-
ing axis). As passive repressors that can interactwith other gene
family members, it is possible that these genesmutually oppose
each other’s expression, and this may contribute to cell state
and fate choices. Supporting such a possibility, we show that in
isolated primary pancreatic islets from Hes3 null mice, the
expression ofHes1, a genewith roles in pancreatic development
(1, 46), is markedly increased. It is possible that other Hes/Hey
genes and other gene families may also be regulated, and this
will be important to address in subsequent studies to identify
genes that may compensate for the absence of Hes3 in the con-
text of development and/or the response to damage. This may
explain our finding that in the Hes3 null-isolated islets, Pdx1
expression appears normal. In contrast, inMIN6 cells subjected
to Hes3 interference, an acutemanipulation that may not allow
for compensatory mechanisms to operate, Pdx1 expression is
markedly reduced.
FIGURE 8. Roles of Hes3 in pancreatic islet function. A, MIN6 cells can be cultured under different culture conditions, in which the role of Hes3 varies. B,
potentially relevant signaling pathways that may intercept with Hes3 include the leptin signaling system and irradiation-induced stresses. In genetic models
of leptin signaling disruption (ob/ob and db/dbmouse strains), Hes3 induction in the pancreatic duct is observed. Likewise inwild-typemice subjected to total
body irradiation. C,Hes3 null mice appear normal with no obvious phenotype. Upon challenge with STZ, however, phenotypes are revealed, including earlier
increases in blood glucose levels and a decreased number of beta cells in the islet, relative to wild-type controls.
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The involvement of JAK in Hes3 regulation deserves addi-
tional study. In NSCs, JAK inhibition promotes Hes3 expres-
sion, especially when combined with cytokine treatments that
activate both the Akt pathway (which leads to STAT3-serine
phosphorylation and Hes3 transcription) and the JAK-STAT
pathway (which suppresses Hes3 transcription), likely because
it promotes the pro-Hes3 function, whereas inhibiting the anti-
Hes3 function (10). In fact, JAK inhibition can convert a pro-
differentiation cytokine (ciliary neurotrophic factor) into a
mitogen that maintains the self-renewal state (10, 12). InMIN6
cells (in CC), leptin induces the activation of MAPK and JAK
and promotes cell proliferation; whereas MAPK inhibition
experiments show that this kinase family mediates prolifera-
tion, it is not clear if JAK also contributes (47).Our observations
using MIN6 cells show no effect of JAK inhibition of the sub-
cellular localization of Hes3 or Pdx1 (control treatment: 19.8
1.3%of cellswith nuclearHes3, 94.1 1.5%of cellswith nuclear
Pdx1; 200 nM JAK inhibitor for 5 days: 22.6 1.9% of cells with
nuclearHes3, 96.4 1.6% of cells with nuclear Pdx1). However,
in primary cultured fetal mouse pancreatic progenitors, JAK
inhibition increases cell yield (10). This could be due to the fact
that, as a transformed cell line, MIN6 cells exhibit skewed JAK
or downstream signaling (48).
A potential clue pointing toward a role of other signaling
pathways, including the JAK pathway in vivo comes from our
observations that inmice with disrupted leptin signaling (ob/ob
and db/dbmouse strains), we observe Hes3 expression outside
the pancreatic islet, and specifically in the ductal epithelium
(Fig. 8B). In contrast, we have never observed such immunola-
beling in wild-type mice. Another indication comes from mice
subjected to total body irradiation, which also exhibit Hes3
expression in the duct. These mousemodels may serve to iden-
tify additional upstream and downstream regulators andmedi-
ators of Hes3. These observations raise an intriguing question:
is the function of Hes3 to stimulate fast proliferation or to
induce cells to partake in the regeneration process by enhanced
survival and cell fate choices? The latter possibility would not
necessarily require a fast proliferation mechanism. The fact
that in DC, MIN6 cells incorporate less EdU than in CC may
support a role in survival over proliferation, although many
other differences in these culture conditions may account for
the EdU incorporation differences. Our results show that under
certain growth conditions that support Hes3 expression, it
plays important roles in regulating their cell number. It will be
of importance to address whether the subcellular localization
or another aspect ofHes3 signaling such as specific interactions
with other proteins or DNA sequences drive this process. Of
course, other differences between the culture conditions may
be responsible for this. Hes3 knockdown experiments support a
role of Hes3 in cell number regulation, but this may be due to
effects on survival and not the regulation of cell number. Addi-
tional experiments with, preferably, primary cell systems that
allow the measurement of proliferative activity and cell cycle
duration, will be required to address this point. In the mean-
time, our previous workwithNSCs showed that treatment with
soluble Notch receptor ligands that induce Hes3 expression
and increase cell number do so not by changing cell cycle dura-
tion but by greatly reducing the probability of cell death (10).
Understanding the signal transduction pathways upstream
and downstreamofHes3may help identify new treatments that
affect pancreatic function.GLP-1 analogs activate theAkt path-
waywhich, inNSCs, leads to phosphorylation of STAT3-serine,
Hes3 transcription, and improved cell survival (10). In MIN6
cells, where Exendin-4 protects against pro-apoptotic insults
(49), high concentrations of Exendin-4 significantly increased
nuclear Hes3 expression in CC and DC. Although in this con-
text it is not clear if changes inHes3 expression/localization are
responsible for the protective effects, it will be of interest to
address this issue, especially with primary cell systems. In CC,
we observe a very low incidence of nuclear Hes3 localization.
Exendin-4, however, induces nuclearHes3 expression, suggest-
ing that it activates a signaling pathway that overrides nuclear
exclusion of Hes3, worthy of additional research. In both CC
and DC we observed more pronounced effects after sustained
exposure to relatively high Exendin-4 concentrations. It is con-
ceivable that a negative feedback mechanism, downstream of
Exendin-4, may limit the extent of the action of Exendin-4 and
that repeat cycles of activation may be necessary for effects to
becomeobvious. For example, inNSCs,Notch ligand activation
induces the phosphorylation of STAT3-serine within20min.
However, the phosphorylation abruptly decreases within
another 20 min, returning to baseline, also suggesting a nega-
tive feedback system. The reduction is observed despite the
continued presence of ligand, suggesting a refractory period
following receptor activation. Such a system could conceivably
involve kinases such as LKB1, which is phosphorylated at
approximately the time that STAT3-serine phosphorylation is
down-regulated (10). However, the functional consequence of
this modification on LKB1 (or potentially others) in NSCs has
not been determined. Regardless, it will be valuable to deter-
mine whether Hes3 is a functional mediator of GLP-1 signaling
and to identify negative feedbackmechanismswhose inhibition
may provide the basis for new therapeutics that will enhance
the efficacy of GLP-1 analogs. Clues to such mechanisms may
be provided by our observations of extra-islet Hes3 expression
in mice that are subjected to irradiation or that have disrupted
leptin signaling.
It will be valuable to investigate further the relationship
between Hes3 and Pdx1. In cells lacking Pdx1, Exendin-4 fails
to promote cell proliferation (50) and future studies may
address if Hes3 is involved in this effect. In this work, we dem-
onstrate that in MIN6 cells, Hes3 regulates Pdx1 expression.
Previous work employing chromatin immunoprecipitation
approaches also on MIN6 cells demonstrated that Pdx1 binds
to the Hes3 promoter (51). Our observations may be uncover-
ing aspects of this reciprocity. In the acute treatment, Hes3
translocation is a more sensitive (and earlier) response than
Pdx1 expression or translocation. In contrast, in the sustained
Exendin-4 experiments, the tables are reversed. Here, nuclear
Pdx1 changes appear at lower concentrations than the ones
needed to observeHes3 changes. These observationsmay serve
as assays to investigate the relationship betweenHes3 and Pdx1
further.
The Hes3 null mouse line is a remarkable one as it has no
evident phenotypes, but the biology behind Hes3 suggests that
its absence should impact the health of the animal (11). It may
Hes3 Regulates Pancreatic Islet Cell Functions
35514 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 51•DECEMBER 19, 2014
 at U
N
IV
 O
F N
O
TTIN
G
H
A
M
 on N
ovem
ber 28, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
be that the answer to this riddle is that Hes3 is not essential
under normal conditions but highly convenient to have in
instances of damage and stress, either because Hes3 absence
can be compensated for under normal conditions by other
genes, or because Hes3 function is primarily allocated to dam-
age situations (Fig. 8C). Here, we employed STZ damage mod-
els to this mouse strain, revealing new phenotypes in line with
this hypothesis. Whereas in normal conditions, glucose toler-
ance test results are indistinguishable between Hes3 null mice
and wild-type controls, following STZ damage we observe an
induction of Hes3a promoter activation (the mouse strain only
allows the assessment of Hes3a promoter activity), a greater
deficit in beta cells, and an earlier diabetic phenotype. Follow-
ing low STZ damage, the percentage of alpha cells in the Hes3
null mice was greater than in the wild-type controls; it will be of
great interest to address whether this reflects the fact that alpha
cells are not affected by the absence of Hes3, despite the fact
that a proportion of them express this transcription factor,
or whether alpha to beta cell conversion may be somehow
impacted by the absence of Hes3. These initial results suggest a
role ofHes3 in the sensitivity of pancreatic beta cells to STZ and
challenge future experiments designed to assess the role of
Hes3 in different paradigms of damage and regeneration.
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